IndraLab
Statements
Hydroxychloroquine inhibits IL6. 59 / 60
|
12
47
reach
"Furthermore, considering that the levels of systemic inflammation biomarkers significantly decreased among good responders in our study, it is notable that methotrexate alone or in combination with sulfasalazine reduces circulating levels of IL-6 [XREF_BIBR], and hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production from PBMC [XREF_BIBR]."
reach
"It could be supposed that vascular microbial penetration during bacteraemia is facilitated by the damaged vascular endothelium, related to COVID-19 and arterial hypertension.The potential iatrogenic immunosuppression induced by Tocilizumab (antagonist of the interleukin-6 receptor), hydroxychloroquine or corticosteroids, after therapeutical used for severe COVID-19, was notified in a third of cases (4/11)."
eidos
"HCQ has also been implicated in the reduction of other anti-inflammatory cytokines ; in vitro studies have shown that HCQ can reduce the production of IL-1 , IL-6 , TNF , INFgamma by mononuclear cells , and reduce TNF , INF , IL-6 , and CCL4 in plasmacytoid dendritic cells ( pDC , an immune cell type linked to viral defense ) and natural killer cell co-cultures ( Wallace et al ., 1993 ; Wallace et al ., 1994 ) ."
reach
"In SLE and RA patients, HCQ affects TLR7 and TLR9 activation and decreases the percentage of DCs as well as their production of IFN-α (Sacre et al., 2012; Alves et al., 2017; Hjorton et al., 2018; Zeidi et al., 2019; Meng et al., 2022), IL-6 (Piconi et al., 2011; Hjorton et al., 2018; Meng et al., 2022) and TNF-α (Sacre et al., 2012; Hjorton et al., 2018; Han et al., 2020)."
reach
"In two clinical trials conducted in the 1990s, Sperber et al. reported suppressive effects on immune activation (measured at that time as IL-6 production) and viral load in individuals treated with 800mg of hydroxychloroquine and day (bioequivalent to 500mg/day of chloroquine) [XREF_BIBR, XREF_BIBR]."